Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19193984 | 0.76 | L3MBTL1 (0.54) | L3MBTL1LMNAPTPRC | |
| SCHEMBL27551142 | 0.76 | L3MBTL1 (0.54) | L3MBTL1LMNAPTPRC | |
| SCHEMBL27570822 | 0.76 | L3MBTL1 (0.54) | L3MBTL1LMNAPTPRC | |
| SCHEMBL2379530 | 0.73 | L3MBTL1 (0.43) | L3MBTL1KDM4EPTPRC | |
| SCHEMBL14208451 | 0.72 | HDAC3 (0.46) | LMNAPTPRC | |
| SCHEMBL1830610 | 0.72 | KDM4E (0.41) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL6178015 | 0.70 | CCNT1 (0.42) | L3MBTL1PTPRCVSIR | |
| SCHEMBL1828340 | 0.70 | HTT (0.39) | L3MBTL1KDM4ETSHRTDP1LMNA | |
| SCHEMBL18157892 | 0.70 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL100967 | 0.70 | KDM4E (0.61) | L3MBTL1KDM4EALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | L3MBTL1 1939/4885KDM4E 2792/4885ALOX15 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.